Cullinan Therapeutics gets EMA approval to begin phase 1 trial of CLN─978, a bispecific CD19 T cell engager administered ...
Cullinan Therapeutics, Inc., a biopharmaceutical company focused on developing modality-agnostic targeted therapies, announced that the European Medicines Agency (EMA) approved the company’s Clinical Trial Application (CTA) for CLN-978. The phase 1 …